[Complimentary Webinar] Key Developments-Genomics in Mesothelioma Cases

December 1st, 1:30 pm - 2:45 pm ET
Perrin Conferences, LLC
Contact
December 1st, 2022
1:30 PM - 2:45 PM ET

Join us for this complimentary CLE webinar on Thursday, December 1, 2022 from 1:30-2:45 pm ET.

Speakers:

Topics for discussion include:

  • Key Litigation Developments
    • Genomic Data Increasingly Found in Medical Records
    • Dr. Testa’s Acknowledgement that Whole Genome Sequencing is Best and Mutations Cannot Be Predicted
    • Concessions that Some BAP1 Mutations Can By Themselves Cause Mesotheliomas and Other Cancers
    • Developments in Alameda County Regarding Genetic Testing
  • Key Scientific Developments
    • Key Points from Carbone 2022 on BAP1 Null Variants
    • Examples of Null BAP1 Variants in Mesotheliomas
    • Roles of BAP1 Protein
    • Tissue Specific Effects Can Explain the Resulting Cancer(s)
  • Key Applications and Uses of Genomic Data
    • Differences Between WGS and WES
    • Understanding Limits of Gene Panels
    • Uses of Both Somatic and Germline Mutation Data
    • Applications Extend Beyond Mesothelioma

To register for this complimentary webinar, click here. Complimentary registration comes with CLE credit in one state and will be available in California, Illinois, New Jersey, New York, Pennsylvania, and Texas.

For more information about registration, contact Amy Williams at awilliams@perrinconferences.com.

PRESENTED BY:

Perrin Conferences, LLC
Contact
more
less

Perrin Conferences, LLC on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.